ADDRESSING KEY TOPICS IN THE MANAGEMENT OF PSORIATIC DISEASE:
HOW WOULD YOU MANAGE THESE PATIENTS?
Major Gheorghe GIURGIU1, Prof. dr. Manole COJOCARU2 SciRes I, EuSpLM
1Deniplant-Aide Sante Medical Center, Biomedicine, Bucharest, Romania
deniplant@gmail.com; Telephone: +40744827881
https://orcid.org/0000-0002-5449-2712
2Titu Maiorescu University, Faculty of Medicine, Bucharest, Romania
cojocaru.manole@gmail.com; Telephone: +40723326663
https://orcid.org/0000-0002-6871-577X
Background Psoriasis is a common and chronic dermatological disease considered as a systemic inflammatory disorder. A growing body of evidence highlights that intestinal dysbiosis is associated with the development of psoriasis. The gut-skin axis is the novel concept of the interaction between skin diseases and microbiome through inflammatory mediators, metabolites and the intestinal barrier. Restoration of the microbiome is a therapeutic strategy for psoriasis.
The objective of this study was to summarize the potential action of Deniplant nutraceuticals in psoriasis on inflammation.
Materials and methods We conducted a systematic review of studies investigating intestinal microbiome in psoriasis. To identify studies comparing gut microbiome composition in patients with psoriasis and normal healthy controls. The use of Deniplant nutraceuticals could be interesting in disease management.
Results However, the association of psoriasis with gut dysbiosis is mainly based on limited studies with small number of patients involved. All studies confirmed the association of psoriasis and gut microbiota dysbiosis. This paper provides a detailed and comprehensive systematic review regarding gut microbiome in patients with psoriasis. It is still not clear whether psoriasis is an effect or a cause of the observed disbalance between beneficial and pathogenic microbes.
Conclusion There is a significant association between alterations in gut microbial composition and psoriasis. More unified methodological standards in large-scale studies are needed to understand microbiota's contribution to psoriasis pathogenesis and its modulation as a potential therapeutic strategy. The changes in microbiome under psoriasis treatment can serve as a potential biomarker of positive response to the Deniplant nutraceuticals.
Keywords: microbiome, psoriasis, gut-skin axis, gut barrier, Deniplant nutraceuticals
HOW WOULD YOU MANAGE THESE PATIENTS?
Major Gheorghe GIURGIU1, Prof. dr. Manole COJOCARU2 SciRes I, EuSpLM
1Deniplant-Aide Sante Medical Center, Biomedicine, Bucharest, Romania
deniplant@gmail.com; Telephone: +40744827881
https://orcid.org/0000-0002-5449-2712
2Titu Maiorescu University, Faculty of Medicine, Bucharest, Romania
cojocaru.manole@gmail.com; Telephone: +40723326663
https://orcid.org/0000-0002-6871-577X
Background Psoriasis is a common and chronic dermatological disease considered as a systemic inflammatory disorder. A growing body of evidence highlights that intestinal dysbiosis is associated with the development of psoriasis. The gut-skin axis is the novel concept of the interaction between skin diseases and microbiome through inflammatory mediators, metabolites and the intestinal barrier. Restoration of the microbiome is a therapeutic strategy for psoriasis.
The objective of this study was to summarize the potential action of Deniplant nutraceuticals in psoriasis on inflammation.
Materials and methods We conducted a systematic review of studies investigating intestinal microbiome in psoriasis. To identify studies comparing gut microbiome composition in patients with psoriasis and normal healthy controls. The use of Deniplant nutraceuticals could be interesting in disease management.
Results However, the association of psoriasis with gut dysbiosis is mainly based on limited studies with small number of patients involved. All studies confirmed the association of psoriasis and gut microbiota dysbiosis. This paper provides a detailed and comprehensive systematic review regarding gut microbiome in patients with psoriasis. It is still not clear whether psoriasis is an effect or a cause of the observed disbalance between beneficial and pathogenic microbes.
Conclusion There is a significant association between alterations in gut microbial composition and psoriasis. More unified methodological standards in large-scale studies are needed to understand microbiota's contribution to psoriasis pathogenesis and its modulation as a potential therapeutic strategy. The changes in microbiome under psoriasis treatment can serve as a potential biomarker of positive response to the Deniplant nutraceuticals.
Keywords: microbiome, psoriasis, gut-skin axis, gut barrier, Deniplant nutraceuticals
Niciun comentariu:
Trimiteți un comentariu